A Study of Docetaxel in Combination With Capecitabine in Stomach and Esophagus Cancers

This study has been terminated.
(Roche has withdrawn support)
Sponsor:
Collaborators:
Aventis Pharmaceuticals
Roche Pharma AG
Information provided by (Responsible Party):
Nathan Bahary, MD, University of Pittsburgh
ClinicalTrials.gov Identifier:
NCT00177255
First received: September 12, 2005
Last updated: December 18, 2013
Last verified: December 2013
  Purpose

This is a phase II study that will investigate weekly dosing of docetaxel in combination with capecitabine in advanced gastric and gastro-esophageal adenocarcinomas.


Condition Intervention Phase
Cancer
Drug: Docetaxel
Drug: Capecitabine
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Study of Weekly Docetaxel (Taxotere®) in Combination With Capecitabine (Xeloda) in Advanced Gastric and Gastro-Esophageal Adenocarcinomas.

Resource links provided by NLM:


Further study details as provided by University of Pittsburgh:

Primary Outcome Measures:
  • median survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To determine response rate [ Time Frame: survival at 2 years ] [ Designated as safety issue: No ]

Enrollment: 43
Study Start Date: April 2005
Study Completion Date: December 2008
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Docetaxel + Capecitabine

Docetaxel 30mg/m2 will be administered as a 30-minute infusion on days 1 and 8. Each cycle will consist of 21 days. Premedication with dexamethasone will be given to all patients receiving weekly docetaxel therapy to reduce the incidence and severity of fluid retention as well as the severity of hypersensitivity reactions. Cycle 2 will begin on day 22.

Capecitabine Capecitabine 825mg/m2 bid (total daily dose 1650mg/m2) will be administered orally for 14 days (days 1-14).

Each cycle will consist of 21 days. Cycle 2 will begin on day 22.

Drug: Docetaxel

Docetaxel 30 mg/m2 will be administered as a 30-minute infusion on days 1 and 8. Each cycle will consist of 21 days.

Cycle 2 will begin on day 22.

Drug: Capecitabine

Capecitabine 825 mg/m2 bid (total daily dose 1650 mg/m2) will be administered orally for 14 days (days 1-14).

Each cycle will consist of 21 days.

Cycle 2 will begin on day 22.

Other Names:
  • Capecitabine 825 mg/m2 bid (total daily dose 1650 mg/m2) will be administered orally for 14 days (days 1-14).
  • Each cycle will consist of 21 days.
  • Cycle 2 will begin on day 22.

Detailed Description:

This is a phase II study that will investigate weekly dosing of docetaxel in combination with capecitabine in advanced gastric and gastro-esophageal adenocarcinomas. Docetaxel 30mg/m2 will be administered on days 1 and 8 of each cycle and capecitabine 825mg/m2 bid (total daily dose 1650mg/m2) will be administered orally for 14 days (days 1-14) of each cycle. Each cycle is 21 days. Subjects will receive unlimited cycles of docetaxel and capecitabine until there is evidence of disease progression or unacceptable side effects.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Have histologically or cytologically confirmed locally advanced (unresectable) or metastatic adenocarcinoma of gastric, gastro-esophageal, or esophageal origin.
  2. Must have measurable or evaluable disease.
  3. Received adjuvant therapy are eligible if adjuvant therapy was given ≥ 6 months prior to the diagnosis of metastatic disease.
  4. Life expectancy greater than 12 weeks.
  5. ECOG performance status < 2.
  6. Adequate organ and marrow function.
  7. Preexisting peripheral neuropathy if present must be grade 0 or 1.
  8. Women and men of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for at least 3 months thereafter. Postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential

Exclusion Criteria:

  1. No chemotherapy or radiotherapy within 4 weeks
  2. Not receiving any other investigational agents or participate in any investigational drug study within 4 weeks preceding the start of study treatment.
  3. Patients with known brain metastases shall be excluded from this clinical trial
  4. Patients with evidence or history of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant that precludes informed consent or interferes with the compliance of oral drug intake will also be excluded.
  5. History of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80.
  6. History of allergic reactions attributed to compounds of similar chemical or biologic composition to docetaxel, capecitabine or 5-FU.
  7. Uncontrolled intercurrent illness
  8. Pregnant or breast feeding women are excluded from this study
  9. Inability to swallow tablets or those who have malabsorptive symptoms will be excluded.
  10. HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with docetaxel or capecitabine.
  11. Prior use of docetaxel or capecitabine is not allowed ( Prior 5FU therapy is allowed).
  12. Treatment for other carcinomas within the last five years, except cured non-melanoma skin and treated in-situ cervical cancer.
  13. Major surgery ( i.e laparotomy, line placement is not considered major surgery)within 4 weeks of the start of study treatment, without complete recovery.
  14. Known, existing uncontrolled coagulopathy.
  15. Patients on anticonvulsants that are metabolized via P450 3A4 pathway.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00177255

Locations
United States, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15232
Sponsors and Collaborators
University of Pittsburgh
Aventis Pharmaceuticals
Roche Pharma AG
Investigators
Principal Investigator: Nathan Bahary, MD University of Pittsburgh
  More Information

No publications provided

Responsible Party: Nathan Bahary, MD, Associate Professor, Department of Medicine, Division of Oncology, University of Pittsburgh
ClinicalTrials.gov Identifier: NCT00177255     History of Changes
Other Study ID Numbers: 04-026
Study First Received: September 12, 2005
Last Updated: December 18, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by University of Pittsburgh:
gastric
stomach
esophagus
esophageal

Additional relevant MeSH terms:
Docetaxel
Capecitabine
Fluorouracil
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Antimetabolites
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on October 01, 2014